• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[临床和实验室化学参数对非霍奇金淋巴瘤病程及预后的意义]

[Significance of clinical and laboratory chemical parameters for the course and prognosis of non-Hodgkin's lymphomas].

作者信息

Steinke B, Mau J

出版信息

Klin Wochenschr. 1986 May 15;64(10):445-51. doi: 10.1007/BF01713170.

DOI:10.1007/BF01713170
PMID:2425124
Abstract

Using a regression model, the prognostic significance of clinical and biochemical parameters as well as of histology was analyzed in a group of 336 patients with Non-Hodgkin's lymphoma. A stochastic process model was used for evaluation of the course of disease. With respect to overall survival, serum-LDH-activity, performance status, and the histologically defined grade of malignancy were found to be the most important prognostic parameters, as well as age, though that to a lesser extent. In the course of disease, stage was the most relevant factor for achievement of a complete remission. In patients without remission, survival was determined mainly by histology and serum-LDH-activity; the latter was also of importance for duration of remission. Our study shows that histology is not the only prognostic factor in NHL but that other parameters, mainly serum-LDH-activity and performance status, also have to be considered in comparing different groups of patients.

摘要

利用回归模型,对336例非霍奇金淋巴瘤患者的临床、生化参数以及组织学的预后意义进行了分析。采用随机过程模型评估疾病进程。就总生存期而言,血清乳酸脱氢酶活性、体能状态、组织学确定的恶性程度等级以及年龄均被发现是最重要的预后参数,尽管年龄的重要性相对较小。在疾病进程中,分期是实现完全缓解的最相关因素。在未缓解的患者中,生存期主要由组织学和血清乳酸脱氢酶活性决定;后者对缓解期的持续时间也很重要。我们的研究表明,组织学并非非霍奇金淋巴瘤唯一的预后因素,在比较不同患者群体时,还必须考虑其他参数,主要是血清乳酸脱氢酶活性和体能状态。

相似文献

1
[Significance of clinical and laboratory chemical parameters for the course and prognosis of non-Hodgkin's lymphomas].[临床和实验室化学参数对非霍奇金淋巴瘤病程及预后的意义]
Klin Wochenschr. 1986 May 15;64(10):445-51. doi: 10.1007/BF01713170.
2
[Prognostic parameters in patients with advanced non-Hodgkin's lymphoma].[晚期非霍奇金淋巴瘤患者的预后参数]
S Afr Med J. 1986 Mar 15;69(6):358-63.
3
Prognostic parameters in low-grade non-Hodgkin's lymphomas.
Neoplasma. 1997;44(1):13-7.
4
Serum lactate dehydrogenase level as a prognostic factor in Hodgkin's disease.血清乳酸脱氢酶水平作为霍奇金病的一个预后因素。
Br J Cancer. 1993 Dec;68(6):1227-31. doi: 10.1038/bjc.1993.509.
5
Prognostic value of serum lactic dehydrogenase in non-Hodgkin's lymphoma.
Scand J Haematol. 1983 Jul;31(1):49-56. doi: 10.1111/j.1600-0609.1983.tb02136.x.
6
Risk-adjusted prognostic models for Hodgkin's disease (HD) and grade II non-Hodgkin's lymphoma (NHL II): validation on 6728 British National Lymphoma Investigation patients.
Br J Haematol. 2003 Jan;120(2):277-80. doi: 10.1046/j.1365-2141.2003.04061.x.
7
Activity of serum thymidine kinase in non-Hodgkin lymphoma: relationship to other prognostic factors.非霍奇金淋巴瘤患者血清胸苷激酶活性:与其他预后因素的关系。
Klin Wochenschr. 1988 Aug 15;66(16):718-23. doi: 10.1007/BF01726414.
8
Prognostic factors in high and intermediate grade non-Hodgkin's lymphoma.高中级非霍奇金淋巴瘤的预后因素
Br J Cancer. 1989 Feb;59(2):276-82. doi: 10.1038/bjc.1989.57.
9
Age and serum lactate dehydrogenase level are independent prognostic factors in human immunodeficiency virus-related non-Hodgkin's lymphomas: a single-institute study of 96 patients.年龄和血清乳酸脱氢酶水平是人类免疫缺陷病毒相关非霍奇金淋巴瘤的独立预后因素:一项对96例患者的单机构研究
J Clin Oncol. 1996 Aug;14(8):2217-23. doi: 10.1200/JCO.1996.14.8.2217.
10
Serum LDH values in childhood acute leukemias and non-Hodgkin's lymphoma.
Med Pediatr Oncol. 1984;12(2):89-92. doi: 10.1002/mpo.2950120205.

本文引用的文献

1
Factors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma.弥漫性混合、组织细胞性或未分化淋巴瘤长期生存的预测因素。
Blood. 1981 Jul;58(1):45-51.
2
Malignant lymphoma. II Prognostic factors and response to treatment of 473 patients at the National Cancer Institute.恶性淋巴瘤。二、国立癌症研究所473例患者的预后因素及治疗反应
Cancer. 1982 Dec 15;50(12):2708-21. doi: 10.1002/1097-0142(19821215)50:12<2708::aid-cncr2820501203>3.0.co;2-g.
3
Treatment of advanced diffuse histiocytic lymphoma: an analysis of prognostic variables.
晚期弥漫性组织细胞淋巴瘤的治疗:预后变量分析
Cancer. 1982 Apr 15;49(8):1571-9. doi: 10.1002/1097-0142(19820415)49:8<1571::aid-cncr2820490809>3.0.co;2-g.
4
Prognostic significance of serum lactate dehydrogenase in malignant lymphoma.
Cancer. 1980 Jul 1;46(1):139-43. doi: 10.1002/1097-0142(19800701)46:1<139::aid-cncr2820460122>3.0.co;2-8.
5
National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project.美国国立癌症研究所资助的非霍奇金淋巴瘤分类研究:临床应用工作方案的总结与描述。非霍奇金淋巴瘤病理分类项目。
Cancer. 1982 May 15;49(10):2112-35. doi: 10.1002/1097-0142(19820515)49:10<2112::aid-cncr2820491024>3.0.co;2-2.
6
A new working formulation of non-Hodgkin's lymphomas. A retrospective study of the new NCI classification proposal in comparison to the Rappaport and Kiel classifications.非霍奇金淋巴瘤的一种新工作分类法。一项将美国国立癌症研究所(NCI)新分类提议与拉帕波特分类法和基尔分类法相比较的回顾性研究。
Cancer. 1983 Sep 1;52(5):833-40. doi: 10.1002/1097-0142(19830901)52:5<833::aid-cncr2820520515>3.0.co;2-r.
7
Prognostic value of serum lactic dehydrogenase in non-Hodgkin's lymphoma.
Scand J Haematol. 1983 Jul;31(1):49-56. doi: 10.1111/j.1600-0609.1983.tb02136.x.
8
Morphological classification of non-Hodgkin malignant lymphoma. II. Comparison between Rappaport's classification and the Kiel classification.
Scand J Haematol. 1983 Jan;30(1):13-24. doi: 10.1111/j.1600-0609.1983.tb00629.x.
9
Prognostic factors in non-Hodgkin's lymphoma: the importance of symptomatic stage as an adjunct to the Kiel histopathological classification.非霍奇金淋巴瘤的预后因素:症状期作为基尔组织病理学分类辅助指标的重要性。
Br J Cancer. 1983 Jan;47(1):91-102. doi: 10.1038/bjc.1983.11.
10
Treatment of diffuse poorly differentiated lymphocytic lymphoma. An analysis of prognostic variables.
Cancer. 1984 Jun 1;53(11):2404-12. doi: 10.1002/1097-0142(19840601)53:11<2404::aid-cncr2820531107>3.0.co;2-f.